Please assess the completion status of the following clinical trial:

Trial Title: Intranasal Steroids and Oxymetazoline in Allergic Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females between 18 and 55 years of age.~2. History of perennial allergic rhinitis.~3. Positive skin test to dust mite, dog, cat or indoor mold antigen.~4. And a combined nasal morning and evening score of ≥4 for nasal congestion in the day preceding entry~Exclusion Criteria:~1. Physical signs or symptoms suggestive of renal, hepatic or cardiovascular disease.~2. Pregnant or lactating women.~3. Subjects treated with systemic steroids during the previous 30 days.~4. Subjects treated with topical (inhaled, intranasal or intraocular) steroids, Nasalcrom or Opticrom during the previous 30 days.~5. Subjects treated with oral antihistamine/decongestants during the previous seven days.~6. Subjects treated with topical (intranasal or intraocular) antihistamine/decongestants during the previous 3 days.~7. Subjects treated with immunotherapy and are escalating their dose.~8. Subjects on chronic anti-asthma medications.~9. Subjects with polyps in the nose or a significantly displaced septum.~10. Upper respiratory infection within 14 days of study start.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Placebo FF + Placebo OXY (Type: PLACEBO_COMPARATOR): Placebo Fluticasone furoate + Placebo Oxymetazoline, 2 puffs of each nasal spray in each nostril in the pm
- FF + Placebo OXY (Type: ACTIVE_COMPARATOR): Fluticasone furoate + Placebo Oxymetazoline, 2 puffs of each nasal spray in each nostril in the pm
- Placebo FF + OXY (Type: ACTIVE_COMPARATOR): Placebo Fluticasone furoate + Oxymetazoline, 2 puffs of each nasal spray in each nostril in the pm
- FF + OXY (Type: ACTIVE_COMPARATOR): Fluticasone furoate + Oxymetazoline, 2 puffs of each nasal spray in each nostril in the pm

Based on this trial design, predict the completion outcome and termination type (if applicable).